Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
AIDS Vaccines
/ immunology
Adult
Antibodies, Neutralizing
/ immunology
Antibody Formation
Broadly Neutralizing Antibodies
/ immunology
CD4 Lymphocyte Count
CD4-CD8 Ratio
Epitope Mapping
Epitopes
/ immunology
Female
HIV Antibodies
/ chemistry
HIV Infections
/ immunology
HIV-1
/ immunology
Host-Pathogen Interactions
/ immunology
Humans
Immunization
Male
Middle Aged
Models, Molecular
Protein Conformation
Structure-Activity Relationship
Vaccines, Virus-Like Particle
/ immunology
env Gene Products, Human Immunodeficiency Virus
/ chemistry
HIV-1
neutralizing antibodies
vaccines
virus-like particles
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
12 01 2022
12 01 2022
Historique:
pubmed:
21
10
2021
medline:
22
2
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Longitudinal studies in HIV-1-infected individuals have indicated that 2 to 3 years of infection are required to develop broadly neutralizing antibodies. However, we have previously identified individuals with broadly neutralizing activity (bNA) in early HIV-1 infection, indicating that a vaccine may be capable of bNA induction after short periods of antigen exposure. Here, we describe 5 HIV-1 envelope sequences from individuals who have developed bNA within the first 100 days of infection (early neutralizers) and selected two of them to design immunogens based on HIV-1-Gag virus-like particles (VLPs). These VLPs were homogeneous and incorporated the corresponding envelopes (7 to 9 μg of gp120 in 10
Identifiants
pubmed: 34668778
doi: 10.1128/JVI.01343-21
pmc: PMC8754226
doi:
Substances chimiques
AIDS Vaccines
0
Antibodies, Neutralizing
0
Broadly Neutralizing Antibodies
0
Epitopes
0
HIV Antibodies
0
Vaccines, Virus-Like Particle
0
env Gene Products, Human Immunodeficiency Virus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0134321Subventions
Organisme : NIAID NIH HHS
ID : P01 AI131568
Pays : United States
Références
J Virol. 2007 Jun;81(12):6548-62
pubmed: 17409160
PLoS Pathog. 2014 Aug 07;10(8):e1004254
pubmed: 25101974
Expert Rev Vaccines. 2016 May;15(5):585-98
pubmed: 26645951
PLoS One. 2018 Dec 19;13(12):e0208345
pubmed: 30566493
PLoS Pathog. 2010 May 27;6(5):e1000908
pubmed: 20523901
J Clin Invest. 2019 Nov 1;129(11):4832-4837
pubmed: 31589168
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
PLoS Pathog. 2016 Nov 16;12(11):e1005989
pubmed: 27851829
J Infect Dis. 2005 Mar 1;191(5):654-65
pubmed: 15688278
PLoS Pathog. 2013 Sep;9(9):e1003618
pubmed: 24068931
J Virol. 1993 Nov;67(11):6642-7
pubmed: 7692082
Curr Opin Virol. 2016 Jun;18:44-9
pubmed: 27039982
J Virol. 2002 Jun;76(11):5315-25
pubmed: 11991960
Retrovirology. 2018 Sep 12;15(1):63
pubmed: 30208933
Vaccine. 2006 Mar 20;24(13):2324-32
pubmed: 16406147
Science. 2002 Jun 28;296(5577):2354-60
pubmed: 12089434
Cell. 2020 Oct 1;183(1):185-196.e14
pubmed: 33007262
Vaccine. 2018 Aug 6;36(32 Pt A):4768-4773
pubmed: 29325819
Cell Rep. 2018 Oct 23;25(4):893-908.e7
pubmed: 30355496
Virology. 2008 Mar 1;372(1):187-200
pubmed: 18031785
J Immunol. 1999 Apr 15;162(8):4796-800
pubmed: 10202022
J Virol. 2002 Sep;76(17):8875-89
pubmed: 12163607
J Virol. 2009 Jan;83(2):757-69
pubmed: 18987148
Vaccine. 2015 Dec 22;33(52):7518-24
pubmed: 26458803
Immunol Rev. 2017 Jan;275(1):161-182
pubmed: 28133806
PLoS One. 2012;7(11):e48848
pubmed: 23144996
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
PLoS One. 2014 Mar 05;9(3):e90581
pubmed: 24599324
Retrovirology. 2018 Jul 28;15(1):52
pubmed: 30055627
J Virol. 2006 Mar;80(5):2515-28
pubmed: 16474158
Front Immunol. 2020 Jun 02;11:984
pubmed: 32582155
J Virol. 2017 Jun 26;91(14):
pubmed: 28446665
J Virol. 2012 Feb;86(4):2045-55
pubmed: 22156522
J Virol. 2003 Jan;77(1):353-65
pubmed: 12477840
Nat Med. 2014 Jun;20(6):655-8
pubmed: 24859529
AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):942-943
pubmed: 27309849
AIDS. 2014 Jan 14;28(2):163-9
pubmed: 24361678
J Virol. 2015 Dec 30;90(6):2806-17
pubmed: 26719252
AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69
pubmed: 7520721
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
Nat Commun. 2019 May 29;10(1):2355
pubmed: 31142746
Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19134-9
pubmed: 17142324
J Virol. 2011 Jun;85(12):5804-13
pubmed: 21471239
J Virol. 2015 Mar;89(6):3380-95
pubmed: 25589637
J Virol. 2018 Apr 13;92(9):
pubmed: 29491151
Cell. 2015 Aug 27;162(5):1090-100
pubmed: 26279189
J Virol. 2012 Apr;86(7):3574-87
pubmed: 22301141
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3809-13
pubmed: 8170992
Virol J. 2012 Sep 18;9:210
pubmed: 22988963
Nature. 2013 Jul 4;499(7456):102-6
pubmed: 23698367
Cell. 2015 Dec 17;163(7):1702-15
pubmed: 26687358
J Virol. 2016 May 12;90(11):5231-5245
pubmed: 26984721
Virology. 2007 Sep 30;366(2):245-62
pubmed: 17580087
Retrovirology. 2013 Sep 23;10:102
pubmed: 24059682
J Virol. 2003 May;77(10):5678-84
pubmed: 12719560
Immunol Rev. 2017 Jan;275(1):21-32
pubmed: 28133813
J Biol Chem. 2019 Apr 5;294(14):5616-5631
pubmed: 30728245
J Virol. 2014 Nov;88(22):12968-81
pubmed: 25122781
PLoS Pathog. 2011 Sep;7(9):e1002209
pubmed: 21980282
J Virol. 2009 Jan;83(1):188-99
pubmed: 18922865
J Virol. 2004 Jul;78(13):6775-85
pubmed: 15194752
J Virol. 2008 Dec;82(23):11651-68
pubmed: 18815292
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
PLoS One. 2015 Aug 10;10(8):e0134054
pubmed: 26258485
AIDS. 2014 May 15;28(8):1237-40
pubmed: 24556870